CLINICAL TRIALS PROFILE FOR VABORBACTAM

Clinical Trials for Vaborbactam

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02166476 ↗	Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP	Completed	Department of Health and Human Services	Phase 3	Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).
NCT02166476 ↗	Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP	Completed	Melinta Therapeutics, Inc.	Phase 3	Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).
NCT02166476 ↗	Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP	Completed	Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)	Phase 3	Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).
NCT02168946 ↗	Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults	Completed	Department of Health and Human Services	Phase 3	Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae
NCT02168946 ↗	Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults	Completed	Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)	Phase 3	Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae
NCT02168946 ↗	Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults	Completed	Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)	Phase 3	Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae
NCT02687906 ↗	Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections	Recruiting	Department of Health and Human Services	Phase 1	A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections

Clinical Trial Conditions for Vaborbactam

Condition Name

Condition Name
Intervention	Trials
Urinary Tract Infection Complicated	2
Ventilator-Associated Bacterial Pneumonia	2
Acute Pyelonephritis	2
Bacterial Infections	1

Condition MeSH

Condition MeSH
Intervention	Trials
Infections	3
Infection	3
Pyelonephritis	2
Pneumonia, Bacterial	2

Clinical Trial Locations for Vaborbactam

Trials by Country

Trials by Country
Location	Trials
United States	28
Brazil	4
Spain	2
Italy	2
Greece	2

Trials by US State

Trials by US State
Location	Trials
New Jersey	3
Illinois	3
Ohio	2
New York	2
Georgia	2

Clinical Trial Progress for Vaborbactam

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	3
Phase 1	2

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	3
Withdrawn	1
Recruiting	1

Clinical Trial Sponsors for Vaborbactam

Sponsor Name

Sponsor Name
Sponsor	Trials
Department of Health and Human Services	3
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)	3
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)	3

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	8
U.S. Fed	4